GlassScriptPhysician profile
Michael Acosta Orozco
NPI 1568467298
$10,970.48
in general payments reported to CMS, 2019-2025
25 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $162 · 2021: $1,158 · 2022: $1,786 · 2023: $2,829 · 2024: $2,867 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,393.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,720.56 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $1,218.15 | 2022-2025 | Xiidra, Miebo, Alden Scleral Zenlens |
| Sight Sciences, INC. | $1,102.60 | 2019-2025 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $844.18 | 2019-2023 | |
| Oyster Point Pharma, INC. | $808.66 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $624.29 | 2019-2025 | Cequa, Xelpros |
| Dompe US, INC. | $589.83 | 2021-2025 | Oxervate |
| Abbvie INC. | $566.32 | 2022-2025 | |
| Alcon Vision LLC | $522.90 | 2019-2025 | Tryptyr, Precision7, Total30 |
| Tearlab Corp | $450.12 | 2023-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Harrow Eye, LLC | $394.22 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $239.40 | 2021-2022 | |
| Allergan, INC. | $205.66 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $147.38 | 2021 | |
| Aerie Pharmaceuticals, INC. | $128.71 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $87.02 | 2019 | |
| Amgen INC. | $82.83 | 2024-2025 | Tepezza |
| Shire North American Group INC | $50.54 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.81 | 2021 | |
| Thea Pharma INC. | $48.58 | 2022-2024 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $24.58 | 2024 | Xdemvy |
| Optos, INC. | $22.39 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.09 | 2022 | |
| Santen INC. | $13.41 | 2023 | Verkazia |
| Coopervision INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Orozco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.